Approved for the treatment of HIV infection.

An integrase inhibitor.

An unboosted integrase inhibitor with a long-half of 14 hours with once daily dosing.

Marketed as Tivicay.

Effective in patients with resistance to the integrase inhibitor, raltegravir.

Results from the 96-week comparison with efavirenz,

SPRING-1 study showed dolutegravir 50mg orally compared to efavirenz was effective at reducing HIV viral load and raising CD4 counts in integrase-naive patients.

Approved for use in a broad population of HIV-infected patients.

Approved for children ages 12 years and older weighing at least 40 kilograms (kg) who have not previously taken other integrase strand transfer inhibitors.[10]

Common side effects of include insomnia and headache.

Associated with a slightly higher prevalence of neural-tube defects when exposed at conception compared with other types of ART exposure.

In combination with abacavir-lamivudine has a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emitricitabine (SINGLE Investigators).

In combination with NRTIs was effective in treating patients with HIV including those with extensive NRTI resistance in whom no NRTIs  were predicted to have activity.

In a trial involving children and adolescents with HIV-1 infection who were starting 1st to 2nd line treatment, dolutegravir based ART was superior to standard care.

It is the preferred agents for HIV in pregnancy.

Leave a Reply

Your email address will not be published. Required fields are marked *